Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223827 · ClinicalTrials.gov registry record · NA

Handheld Point of Care Electro-Diagnostic Device

A NA study of Neurologic Findings, sponsored by Indiana University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT07223827: Recruiting NA study of Neurologic Findings, sponsored by Indiana University.

NCT07223827 is a NA study of Neurologic Findings that is actively recruiting participants, run by Indiana University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223827, a NA study of Neurologic Findings, is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

There are currently several products offering POC EEG, intended to be deployed on each patient individually and continuously. The investigators propose studying a different approach by using a migrating POC electrodiagnostic device that is deployed directly by the onsite provider and is actively used, like other POC devices, to acquire real-time diagnostic insight and facilitate immediate medical decision making. This can significantly shorten time to treatment which in several neurological and neurosurgical conditions, and thus, can significantly improve patient outcome. The investigational POC investigational device is based on a handheld limited electrode array, complemented by various stimulation modalities such as SSEP, VEP and BAEP, and potentially other sensors. For this study, the investigators intend to use readily available industry standard stimulators and only use the proposed POC investigational device to acquire and analyze the data. The POC investigational electrodiagnostic prototype was assembled using OpenBCI8 electronic board and electrodes, based on ADS 129X chip by Texas Instruments, that was shown to provide an adequate low-cost solution for electrodiagnostic data acquisition.

Primary Outcome

The diagnostic insights acquired using the POC investigation device regarding lateralization (left/right), localization (cerebral - frontal, temporal, parieto-occipital; spinal - cervical, thoracal, lumbosacral; or radicular), and presumed nature of lesion (i.e. ischemia, hemorrhage, space-occupying lesion), are significantly comparable to, and congruent with, the SOC diagnostic insight regarding same parameters (lateralization, localization and presumed etiology) acquired using SOC techniques s

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST POC EEG

Study Locations (1)

Indiana

  • Indiana University Health - Indianapolis

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-01-10
Est. Completion 2026-12
Phase NA
Indiana University

890 total trials

What NCT07223827 shows while recruiting

NCT07223827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Neurologic Findings appearing as the primary indexed condition, and to 1 intervention - of which POC EEG is the first listed.

NCT07223827 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT07223827 about?

NCT07223827 is a clinical study titled "Handheld Point of Care Electro-Diagnostic Device". There are currently several products offering POC EEG, intended to be deployed on each patient individually and continuously. The investigators propose studying a different approach by using a migrating POC electrodiagnostic device that is deployed directly by the onsite provider and is actively use...

What is the current status of trial NCT07223827?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-01-10. Estimated completion is 2026-12.

What conditions does trial NCT07223827 study?

This clinical trial studies the following conditions: Neurologic Findings.

What interventions are being tested in trial NCT07223827?

The interventions under investigation include: POC EEG (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07223827?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223827 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT07223827's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07223827, the US trial registry maintained by the National Library of Medicine. NCT07223827 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.